Orchard Therapeutics plc
ORTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $177 | $99 | $76 | $47 |
| - Cash | $23 | $38 | $61 | $68 |
| + Debt | $48 | $51 | $53 | $58 |
| Enterprise Value | $201 | $111 | $68 | $37 |
| Revenue | $6 | $7 | $1 | $7 |
| % Growth | -13.8% | 491.3% | -82.3% | – |
| Gross Profit | $5 | $5 | $1 | $9 |
| % Margin | 72.3% | 70.1% | 70.3% | 127.3% |
| EBITDA | -$35 | -$20 | -$20 | $134 |
| % Margin | -549.4% | -266.8% | -1,590.6% | 1,915.2% |
| Net Income | -$35 | -$12 | -$17 | $135 |
| % Margin | -560.4% | -168.3% | -1,407.6% | 1,930.9% |
| EPS Diluted | -1.55 | -0.65 | -1.23 | 10.52 |
| % Growth | -138.5% | 47.2% | -111.7% | – |
| Operating Cash Flow | -$24 | -$28 | -$30 | -$12 |
| Capital Expenditures | -$0 | $0 | -$1 | -$0 |
| Free Cash Flow | -$24 | -$28 | -$30 | -$13 |